Axonis Therapeutics, Inc.

Development of KCC2 Neuromodulators to Treat Paralysis After Spinal Cord Injury. - Development of KCC2 Neuromodulators to Treat Spinal Cord Injury. Abstract: There Are No Approved Therapies for Treating Paralysis After Spinal Cord Injury (sci), Despite Roughly 17,000 People Suffering Sci Per Year and About 300,000 People Living With Chronic Sci in Us. for the Vast Majority of Patients, Injury Leaves Them Incapable of Walking or, If They Have Suffered a Cervical Sci, Entirely Dependent Upon Others for Assistance in All of Their Activities of Daily Living From Feeding to Personal Care. the Cost to These Individuals, and to Society as a Whole, Are Significant as Sci Often Occurs in Adults During Their Peak Earning Years. Neuromodulation After Sci Has the Potential to Restore Functions, as Shown Even in Chronic Sci Patients Using Epidural Electrical Stimulation in Clinical Case Studies. We Are Developing a Non-invasive, Oral Neuromodulating Drug That Can Widely Treat the Majority of Sci Patients Who Have Spared, But Dysfunctional, Spinal Cord Tissue. After Sci There Is an Excitation/inhibition Imbalance in the Spared Spinal Cord Tissue That Leads to Paralysis, Spasticity and Neuropathic Pain. This Imbalance Is Caused by a Decrease in the CNS- Specific Chloride Transporter Called KCC2. Indeed, Restoring KCC2 by Both Pharmacological and Genetic Methods in Spared Spinal Cord Neurons Leads Severely Paralyzed Rodents to Regain Stepping Ability. Furthermore, KCC2 Enhancer Drugs Reduce Neuropathic Pain and Spasticity in Rodent Models. in This Application, We Propose to Carry Out Non-glp and GLP Ind-enabling Preclinical Research on Drug Efficacy and Safety of Our Novel KCC2 Enhancer Drug, AXN-006. After Completion of the Proposed Aims, Axonis Goal Is to Be Ready to Commission GMP Drug Product Manufacturing, File an Ind and Move Rapidly Into a First-in-human Phase 1 Clinical Trial in Healthy Volunteers. the Overarching Goal Is the Commercialization of a First-in-class Oral KCC2 Enhancer Drug to Treat Paralysis, Pain and Spasticity in Sci, as Well as Other Relevant Neurological Disorder Indications.